While the future of Celgene (NASDAQ:CELG) looks bright in terms of the company's promising pipeline, its present is facing some serious threats. In this video, Fool health-care analyst David Williamson tells investors how the company's present success is absolutely tied to its two key drugs, Revlimid and Vidaza. David highlights the threats to these drugs both in the form of generics, as well as very fierce competition.